A logical network-based drug-screening platform for Alzheimer's disease representing pathological features of human brain organoids
- Nat Commun. 2021 Jan 12;12(1):280. doi: 10.1038/s41467-020-20440-5.
- 1. Department of Biochemistry and Biomedical Sciences, College of Medicine, Seoul National University, Seoul, 03080, Republic of Korea.
- 2. Neuroscience Research Institute, Medical Research Center, College of Medicine, Seoul National University, Seoul, 03080, Republic of Korea.
- 3. SNU Dementia Research Center, College of Medicine, Seoul National University, Seoul, 03080, Republic of Korea.
- 4. Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, United Kingdom.
- 5. Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, 34141, Republic of Korea.
- 6. Department of Brain and Cognitive Science, Daegu Gyeongbuk Institute of Sciences and Technology (DGIST), Daegu, 42988, Republic of Korea.
- 7. Institute of Human Behavioral Medicine, Medical Research Center, Seoul National University, Seoul, 03080, Republic of Korea.
- 8. Department of Psychiatry, College of medicine, Seoul National University, Seoul, 03080, Republic of Korea.
- 9. Department of Neuropsychiatry, Seoul National University Hospital, Seoul, 03080, Republic of Korea.
- 10. Department of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam, 13620, Republic of Korea.
- 11. Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, 34141, Republic of Korea. [email protected].
- 12. Department of Biochemistry and Biomedical Sciences, College of Medicine, Seoul National University, Seoul, 03080, Republic of Korea. [email protected].
- 13. Neuroscience Research Institute, Medical Research Center, College of Medicine, Seoul National University, Seoul, 03080, Republic of Korea. [email protected].
- 14. SNU Dementia Research Center, College of Medicine, Seoul National University, Seoul, 03080, Republic of Korea. [email protected].
Developing effective drugs for Alzheimer's disease (AD), the most common cause of dementia, has been difficult because of complicated pathogenesis. Here, we report an efficient, network-based drug-screening platform developed by integrating mathematical modeling and the pathological features of AD with human iPSC-derived cerebral organoids (iCOs), including CRISPR-Cas9-edited isogenic lines. We use 1300 organoids from 11 participants to build a high-content screening (HCS) system and test blood-brain barrier-permeable FDA-approved drugs. Our study provides a strategy for precision medicine through the convergence of mathematical modeling and a miniature pathological brain model using iCOs.
-
Cat. No.Product NameCategory/Application